HF-158K1 by HighField Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Disgraced Surgeon Paolo Macchiarini Sees New Wave of Media Attention

A wave of media has brought renewed attention to the cautionary tale of disgraced surgeon, Paolo Macchiarini, MD. Although Macchiarini is now known for his

December 1, 2023

DocMorris demands fully digital non-discriminatory access to e-prescriptions – Biotech Investments

DocMorris AG / Key word(s): Market Report DocMorris AG: DocMorris demands fully digital non-discriminatory access to e-prescriptions 06.07.2023 / 18:11 CET/CEST Frauenfeld, 6 July 2023

July 7, 2023

Binge-eating disorder persists longer than previously thought, study shows

Binge-eating disorder is the most prevalent eating disorder in the United States, but previous studies have presented conflicting views of the disorder’s duration and the

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.